Evidence map›Paper›PMID 25997678›Full record

ArticleBiotechnology and bioengineering2015

Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design.

Shih-Yeh Lin, Chia-Tsui Yeh, Wan-Hua Li, Cheng-Ping Yu, Wen-Chin Lin, Jyh-Yuan Yang, Hsueh-Ling Wu, Yu-Chen Hu

Open access · bronzeAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Shih-Yeh LinDepartment of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
Chia-Tsui YehInstitute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
Wan-Hua LiDepartment of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
Cheng-Ping YuInstitute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
Wen-Chin LinInstitute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
Jyh-Yuan YangCenter for Research, Diagnostics and Vaccine Development, Centers for Disease Control, Taipei, Taiwan.
Hsueh-Ling WuInstitute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
Yu-Chen HuDepartment of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan. ychu@mx.nthu.edu.tw.
National Tsing Hua University · TWDevelopment Center for Biotechnology · TWNational Chung Hsing University · TWNational Defense Medical Center · TWNational Taiwan Normal University · TWTri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterovirus 71 (EV71) is responsible for the outbreaks of hand-foot-and-mouth disease in the Asia-Pacific region. To produce the virus-like particle (VLP) vaccine, we previously constructed recombinant baculoviruses to co-express EV71 P1 polypeptide and 3CD protease using the Bac-to-Bac(®) vector system. The recombinant baculoviruses resulted in P1 cleavage by 3CD and subsequent VLP assembly in infected insect cells, but caused either low VLP yield or excessive VLP degradation. To tackle the problems, here we explored various expression cassette designs and flashBAC GOLD™ vector system which was deficient in v-cath and chiA genes. We found that the recombinant baculovirus constructed using the flashBAC GOLD™ system was insufficient to improve the EV71 VLP yield. Nonetheless, BacF-P1-C3CD, a recombinant baculovirus constructed using the flashBAC GOLD(TM) system to express P1 under the polh promoter and 3CD under the CMV promoter, dramatically improved the VLP yield while alleviating the VLP degradation. Infection of High Five(TM) cells with BacF-P1-C3CD enhanced the total and extracellular VLP yield to ≈268 and ≈171 mg/L, respectively, which enabled the release of abundant VLP into the supernatant and simplified the downstream purification. Intramuscular immunization of mice with 5 μg purified VLP induced cross-protective humoral responses and conferred protection against lethal virus challenge. Given the significantly improved extracellular VLP yield (≈171 mg/L) and the potent immunogenicity conferred by 5 μg VLP, one liter High Five(TM) culture produced ≈12,000 doses of purified vaccine, thus rendering the EV71 VLP vaccine economically viable and able to compete with inactivated virus vaccines.

Indexed as

BaculoviridaeAnimalsAntibodies, ViralAsiaDisease Models, AnimalEnterovirus A, HumanEnterovirus InfectionsGenetic VectorsInjections, IntramuscularInsectaMiceRecombinant ProteinsSurvival AnalysisVaccines, Virus-Like ParticleViral ProteinsVirosomesAntibodies, ViralRecombinant ProteinsVaccines, Virus-Like ParticleViral ProteinsVirosomesbaculovirusEV71hand-foot-and-mouth diseaseproteasevaccineVLP

Identifiers

PMID25997678
PMCPMC7161748
OpenAlexW2134758140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.